|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: DZIP1L |
Gene summary for DZIP1L |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | DZIP1L | Gene ID | 199221 |
| Gene name | DAZ interacting zinc finger protein 1 like | |
| Gene Alias | DZIP2 | |
| Cytomap | 3q22.3 | |
| Gene Type | protein-coding | GO ID | GO:0003002 | UniProtAcc | Q8IYY4 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 199221 | DZIP1L | LZE2T | Human | Esophagus | ESCC | 8.11e-03 | 5.03e-01 | 0.082 |
| 199221 | DZIP1L | LZE4T | Human | Esophagus | ESCC | 9.19e-06 | 2.69e-01 | 0.0811 |
| 199221 | DZIP1L | LZE7T | Human | Esophagus | ESCC | 4.56e-02 | 1.66e-01 | 0.0667 |
| 199221 | DZIP1L | P2T-E | Human | Esophagus | ESCC | 3.19e-23 | 3.93e-01 | 0.1177 |
| 199221 | DZIP1L | P4T-E | Human | Esophagus | ESCC | 2.14e-07 | 1.79e-01 | 0.1323 |
| 199221 | DZIP1L | P5T-E | Human | Esophagus | ESCC | 2.03e-09 | 1.95e-01 | 0.1327 |
| 199221 | DZIP1L | P9T-E | Human | Esophagus | ESCC | 6.56e-16 | 3.68e-01 | 0.1131 |
| 199221 | DZIP1L | P10T-E | Human | Esophagus | ESCC | 5.95e-29 | 5.27e-01 | 0.116 |
| 199221 | DZIP1L | P11T-E | Human | Esophagus | ESCC | 4.36e-04 | 1.81e-01 | 0.1426 |
| 199221 | DZIP1L | P12T-E | Human | Esophagus | ESCC | 8.40e-04 | 9.69e-02 | 0.1122 |
| 199221 | DZIP1L | P15T-E | Human | Esophagus | ESCC | 1.45e-20 | 5.67e-01 | 0.1149 |
| 199221 | DZIP1L | P16T-E | Human | Esophagus | ESCC | 5.86e-08 | 1.43e-01 | 0.1153 |
| 199221 | DZIP1L | P20T-E | Human | Esophagus | ESCC | 9.33e-13 | 3.63e-01 | 0.1124 |
| 199221 | DZIP1L | P21T-E | Human | Esophagus | ESCC | 3.97e-04 | 8.19e-02 | 0.1617 |
| 199221 | DZIP1L | P22T-E | Human | Esophagus | ESCC | 4.16e-22 | 3.71e-01 | 0.1236 |
| 199221 | DZIP1L | P23T-E | Human | Esophagus | ESCC | 2.28e-04 | 1.60e-01 | 0.108 |
| 199221 | DZIP1L | P24T-E | Human | Esophagus | ESCC | 4.40e-09 | 2.18e-01 | 0.1287 |
| 199221 | DZIP1L | P27T-E | Human | Esophagus | ESCC | 3.97e-04 | 1.35e-01 | 0.1055 |
| 199221 | DZIP1L | P28T-E | Human | Esophagus | ESCC | 1.62e-13 | 2.49e-01 | 0.1149 |
| 199221 | DZIP1L | P30T-E | Human | Esophagus | ESCC | 8.25e-24 | 7.53e-01 | 0.137 |
| Page: 1 2 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00219159 | Esophagus | ESCC | neural tube development | 101/8552 | 152/18723 | 1.78e-07 | 2.79e-06 | 101 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| DZIP1L | SNV | Missense_Mutation | c.2257N>C | p.Gly753Arg | p.G753R | Q8IYY4 | protein_coding | deleterious(0.01) | benign(0.372) | TCGA-AO-A0J4-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | |
| DZIP1L | SNV | Missense_Mutation | novel | c.2115N>T | p.Arg705Ser | p.R705S | Q8IYY4 | protein_coding | tolerated(0.2) | benign(0.003) | TCGA-BH-A0B6-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| DZIP1L | SNV | Missense_Mutation | rs374326524 | c.697N>T | p.Arg233Trp | p.R233W | Q8IYY4 | protein_coding | deleterious(0.04) | probably_damaging(0.981) | TCGA-BH-A0RX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | fluorouracil | SD |
| DZIP1L | SNV | Missense_Mutation | c.2282N>T | p.Gln761Leu | p.Q761L | Q8IYY4 | protein_coding | tolerated(0.25) | benign(0.018) | TCGA-C8-A1HJ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| DZIP1L | insertion | Nonsense_Mutation | novel | c.1242_1243insCTGTAGAATTTTTGATGCAGTC | p.Lys415LeufsTer2 | p.K415Lfs*2 | Q8IYY4 | protein_coding | TCGA-A2-A0EX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | ||
| DZIP1L | insertion | In_Frame_Ins | novel | c.2230_2231insATTACCACCTCCACCTCACCCAGACTTCCTTTGACCTTTGGGTGGTCC | p.Ser744delinsTyrTyrHisLeuHisLeuThrGlnThrSerPheAspLeuTrpValValPro | p.S744delinsYYHLHLTQTSFDLWVVP | Q8IYY4 | protein_coding | TCGA-AO-A0J9-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cyclophosphamide | PD | ||
| DZIP1L | deletion | Frame_Shift_Del | novel | c.1588delN | p.Val530CysfsTer55 | p.V530Cfs*55 | Q8IYY4 | protein_coding | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | ||
| DZIP1L | SNV | Missense_Mutation | c.729N>C | p.Gln243His | p.Q243H | Q8IYY4 | protein_coding | tolerated(0.06) | benign(0.074) | TCGA-DS-A0VK-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | carboplatin | PD | |
| DZIP1L | SNV | Missense_Mutation | c.1774N>G | p.Pro592Ala | p.P592A | Q8IYY4 | protein_coding | tolerated(0.05) | possibly_damaging(0.505) | TCGA-EK-A3GK-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| DZIP1L | SNV | Missense_Mutation | c.2140N>G | p.Gln714Glu | p.Q714E | Q8IYY4 | protein_coding | deleterious(0) | probably_damaging(0.931) | TCGA-IR-A3LL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| Page: 1 2 3 4 5 6 7 8 9 10 11 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |